Company Overview of Salix Pharmaceuticals Ltd.
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. It provides Xifaxan tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; Apriso to maintain remission of ulcerative colitis (UC); Moviprep and Osmoprep for cleansing of the colon as a preparation for colonoscopy in adults; Relistor for the treatment of opioid-induced constipation in patients with advanced illness; Solesta to treat fecal incontinence; and Deflux to treat vesicoureteral reflux. It also offers Fulyzaq for the symptomatic relief of non-infectious diarrhea in adult patients with...
8510 Colonnade Center Drive
Raleigh, NC 27615
Founded in 1989
Key Executives for Salix Pharmaceuticals Ltd.
Founder and Chief Scientific Liaison
General Counsel, Executive Vice President, Secretary and Director
Associate Vice President of Investor Relations & Corporate Communications
Compensation as of Fiscal Year 2015.
Salix Pharmaceuticals Ltd. Key Developments
Salix Pharmaceuticals Ltd. Reports Sale Results for the Third Quarter Ended September 30, 2015; Provides Revenue Guidance for 2015
Oct 19 15
Salix Pharmaceuticals Ltd. reported sale results for the third quarter ended September 30, 2015. For the quarter, the company reported revenue of $461 million.
For the full year of 2015, the company expects revenue to be $1.35 billion.
FDA Grants RUCONEST (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity
Oct 8 15
Pharming Group NV and Salix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg. The determination of exclusivity ensures that FDA will not approve before July 16, 2026 any applications for biosimilars of RUCONEST- i.e. applications for recombinant C1 esterase inhibitors referencing RUCONEST submitted under section 351(k) of the Public Health Service Act under the framework established by the Biologics Price Competition and Innovation Act of 2009. RUCONEST was approved by the FDA on July 16, 2014, for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness was not established in HAE patients with laryngeal attacks. A rare condition occurring in about 1 in 10,000 to 1 in 50,000 people worldwide, HAE is potentially life-threatening and stems from a genetic defect that impacts the production of C1-INH protein. This can lead to a biochemical imbalance that causes swelling in various parts of the body, including the hands, feet and face. Swelling in the intestinal wall can also cause severe abdominal pain, nausea and vomiting. Due to its rarity, many patients often remain undiagnosed for years. RUCONEST is contraindicated in patients with a history of allergy to rabbits, or rabbit-derived products, and patients with a history of life-threatening immediate hypersensitivity reactions to C1 esterase preparations, including anaphylaxis. Under the Biologics Price Competition and Innovation Act of 2009, exclusivity for licensed biologics-like RUCONEST-can be granted for a 12-year period from the date of first licensure of the product.
RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals
Jul 27 15
RedHill Biopharma Ltd. has provided an update on its RHB-106 tasteless solid oral formulation bowel preparation development program under the worldwide exclusive license agreement with Salix Pharmaceuticals Ltd., recently acquired by Valeant Pharmaceuticals International Inc. Salix confirmed to RedHill that it continues the development of RHB-106. Salix further clarified to RedHill that the bowel purgative product referenced in Valeant's second quarter 2015 financial results presentation1 as a failed toxicology screen is not RedHill's RHB-106. RHB-106 is an encapsulated formulation intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures, including diagnostic tests such as colonoscopies, barium enemas or virtual colonoscopies, as well as surgical interventions, such as laparotomies. RHB-106 is a tasteless solid oral dosage potentially allowing an unobstructed procedure with reduced side effects and improved compliance. It is also intended to prevent patient exposure to the often unappealing taste of current products.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 11, 2015
February 22, 2015